President and Chief Executive Officer
John Vavricka brings to Iroko over 20 years of broad international experience in the pharmaceutical industry and a demonstrated capacity to build high-performing organizations. Since Mr Vavricka co-founded Iroko in 2007, the company has assembled a workforce led by a seasoned management cadre, acquired 4 prescription pharmaceuticals, established sales and distribution networks in more than 40 countries, and created an R&D portfolio of 8 development programs in mid- to late-phase clinical studies.
Most recently, Mr Vavricka has been leading Irokos initiative to become a leading pain-medicine company both by expanding its base business and applying new technologies to established products to enhance their benefits. The company is an industry leader using nanotechnology to develop new formulations of NSAIDs (non-steroidal anti-inflammatory drugs), one of the largest classes of pain medicines.
Previously, at Chiron Vaccines, Mr Vavricka served as Vice President, US and European Commercial Operations. He established the North American vaccine headquarters and assumed management roles ranging from marketing to compliance to public policy. Upon Chiron's merger with Novartis, he facilitated Chiron's integration and developed the market-expansion strategy for the new Novartis Vaccines.
At GlaxoSmithKline, as Vice President, Marketing, Mr Vavricka led the integration of GSKs predecessor companies in Canada and held P&L responsibility for a $1-billion pharmaceutical business. Earlier, as Vice President, Global Product Strategy, R&D, he headed strategy and commercial development for cardiovascular and urogenital therapies. At SmithKline Beecham, Mr Vavricka held positions of increasing responsibility, lastly as Regional Vice President, Sales, a position in which he was directly accountable for $280 million of sales.
Mr Vavricka holds a B.A. degree in Neurobiology/Physiology from Northwestern University.